PharmD 2007 University of Southern California

MS 2008 University of Washington

PhD 2012 University of Washington
 

University of Washington/Allergan Health Economics and Outcomes Research Fellowship (2007-2009)

Long-Term Care Pharmacist in California and Washington State

Watanabe JH, Bounthavong M, Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin. 2013 Feb 1. [Epub ahead of print] PubMed PMID: 23320610.

Ney JP, van der Goes DN, Watanabe JH. Cost-effectiveness of intraoperative neurophysiological monitoring for spinal surgeries: Beginning steps. Clin Neurophysiol. 2012 Sep;123(9):1705-7. Epub 2012 Mar 3. PubMed PMID: 22386320.

Watanabe JH, Ney JP. Once-daily generic anticholinergics for overactive bladder: meta-
analysis of oxybutynin extended-release randomized trials. Am J Pharm Benefits. 2011;3(5):e85-e92.

Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin. 2011 May;27(5):1041-8. Epub 2011 Mar 21. PubMed PMID: 21417803.

Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 1;28(2):151-60. doi: 10.2165/11586740-000000000-00000. PubMed PMID: 21275440.

Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010 Oct;76(4):835-40. PubMed PMID: 20430422.

Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol. 2009 Nov 20;9:18. Review. PubMed PMID: 19930578; PubMed Central PMCID: PMC2788579.

Jonathan received his PharmD from the University of Southern California in 2007. He completed a MS with the Pharmaceutical Outcomes Research and Policy Program (PORPP) at the University of Washington in 2008 as a component of the University of Washington/Allergan Health Economics and Outcomes Research Fellowship (2007-2009). In 2009, Dr. Watanabe returned to PORPP to pursue a PhD that was defended in 2012. His research areas include pharmaceutical and health policy analysis, pharmacoepidemiology, and health services research focusing on health disparities. He practices in long-term care pharmacy.